This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

SiLaC Laser Technique for Pilonidal Sinus - La Paz Cohort Study.

Sponsored by Hospital Universitario La Paz

About this trial

Last updated 5 months ago

Study ID

Hospital Universitario La Paz

Status

Not yet recruiting

Type

Observational

Placebo

No

Accepting

18+ Years
All Sexes

Trial Timing

Started 5 months ago

What is this trial about?

Pilonidal sinus disease (PSD) is a chronic inflammatory condition of the sacrococcygeal region that frequently affects young adults, often causing pain, drainage, and recurrent infection. Traditional surgical approaches such as wide excision or flap techniques may result in prolonged healing times, relevant postoperative pain, and recurrence rates up to 20-30%. The SiLaC (Sinus Laser-Assisted Closure) technique is a minimally invasive procedure that uses a 1470-nm diode laser fiber to ablate the sinus epithelium and induce concentric contraction of the tract. International studies have reported promising results with faster recovery, minimal wound care, and low morbidity. This prospective single-center cohort study aims to evaluate the clinical outcomes and perceived recovery time of adult patients treated with the SiLaC® technique at Hospital Universitario La Paz (Madrid, Spain). The main outcome is the total recovery time perceived by patients after surgery. Secondary outcomes include postoperative complications, recurrence rate, pain intensity, need for wound care, and patient satisfaction. Data will be collected from medical records and structured follow-up interviews.

What are the participation requirements?

Inclusion Criteria

* Age ≥ 18 years.

* Clinical diagnosis of chronic pilonidal sinus disease.

* Undergoing surgery using the SiLaC (Sinus Laser-Assisted Closure) technique.

* Signed informed consent for the use of anonymized clinical data for research purposes.

Exclusion Criteria

* Patients with inflammatory bowel disease or complex anorectal fistulas.

* Severe immunosuppression (active chemotherapy, high-intensity immunosuppressive therapy, uncontrolled HIV).

* Prior pelvic radiotherapy.

* Missing essential clinical data required for outcome assessment